Clinical Trial Update: Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of LY573636-sodium with liposomal doxorubicin in patients with advanced solid tumors has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• LY573636-sodium
• liposomal doxorubicin (doxorubicin liposomal)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Solid Tumors | Phase 1 | Status: COMPLETED | Results posted: 2018-10-16